NASDAQ:SNSS Sunesis Pharmaceuticals (SNSS) Stock Price, News & Analysis → Trump’s Gift Could Unleash $51 Billion in New Wealth (From Wealthpin Pro) (Ad) Free SNSS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$2.38▼$5.3252-Week Range N/AVolume1.20 million shsAverage Volume4.33 million shsMarket Capitalization$96.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Sunesis Pharmaceuticals alerts: Email Address Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. About Sunesis Pharmaceuticals Stock (NASDAQ:SNSS)Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.Read More Ad Crypto 101 Media[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Did you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum steal all the headlines… It’s often the cryptos flying under the radar that turn small stakes into life-changing windfalls. Claim your free seat by clicking here now. SNSS Stock News HeadlinesDecember 20, 2023 | seekingalpha.comAQSZF Aequus Pharmaceuticals Inc.August 6, 2022 | thestreet.com4 Breakout Stocks to Watch Going Into Labor DayJanuary 14, 2022 | thestreet.com4 Stocks Under $10 to Trade NowSee More Headlines Receive SNSS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunesis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2020Today6/02/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:SNSS CUSIP86732860 CIK1061027 Webwww.sunesis.com Phone650-266-3500FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-179.05% Return on Assets-72.27% Debt Debt-to-Equity RatioN/A Current Ratio7.74 Quick Ratio7.74 Sales & Book Value Annual Sales$2.07 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / BookN/AMiscellaneous Outstanding Shares18,093,000Free FloatN/AMarket Cap$96.26 million OptionableOptionable Beta2.27 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Judith A. Fox (Age 64)Chief Scientific Officer and Exec. VP of R&D Comp: $562.19kMr. Parvinder S. Hyare (Age 50)Interim CEO & Principal Exec. Officer Ms. Tina Gullotta (Age 46)Principal Financial Officer, VP of Fin. & Principal Accounting Officer Dr. Deborah A. ThomasSr. VP, Regulatory Affairs, Quality Assurance & PharmacovigilanceMr. Daniel N. Swisher Jr. (Age 58)Strategic Advisor Key CompetitorsAgenusNASDAQ:AGENXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDAEmergent BioSolutionsNYSE:EBSCodexisNASDAQ:CDXSView All Competitors SNSS Stock Analysis - Frequently Asked Questions How were Sunesis Pharmaceuticals' earnings last quarter? Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) released its earnings results on Sunday, November, 15th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.01. When did Sunesis Pharmaceuticals' stock split? Sunesis Pharmaceuticals shares reverse split on Thursday, September 3rd 2020. The 1-10 reverse split was announced on Wednesday, September 2nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 2nd 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What is Dan Swisher Jr.'s approval rating as Sunesis Pharmaceuticals' CEO? 4 employees have rated Sunesis Pharmaceuticals Chief Executive Officer Dan Swisher Jr. on Glassdoor.com. Dan Swisher Jr. has an approval rating of 82% among the company's employees. What other stocks do shareholders of Sunesis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include Amarin (AMRN), QUALCOMM (QCOM), Actinium Pharmaceuticals (ATNM), NVIDIA (NVDA), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Exelixis (EXEL) and Novavax (NVAX). This page (NASDAQ:SNSS) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking $16T Elon Musk Crypto LeakCrypto 101 MediaBiden replacement revealed?Paradigm PressWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsHow Biden has already won 2024Porter & CompanyThis unknown company solves the biggest issue with AIManward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunesis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.